促甲状腺激素抑制疗法对甲状腺癌术后患者预后及癌周组织TIPE2、STAT3表达的影响  

Effect of Thyroid Stimulating Hormone Inhibition Therapy on the Prognosis of Thyroid Cancer and the Expression of TIPE2 and STAT3 in Pericancerous Tissues

作　　者：魏巧兰[1] 李和玲 张斌[1] 

机构地区：[1]河南省济源市人民医院,454900

出　　处：《实用癌症杂志》2017年第8期1260-1263,1266,共5页The Practical Journal of Cancer

摘　　要：目的探讨促甲状腺激素抑制疗法(TSHIT)对甲状腺癌手术患者预后的影响,及对切除癌组织周围组织中肿瘤坏死因子诱导蛋白8样蛋白2(TIPE2)、信号转导子和转录激活因子(STAT3)表达的影响。方法选择88例甲状腺癌患者为研究对象。所有患者均行手术切除治疗,根据术后是否采用TSH抑制疗法将其分为对照组(47例)和观察组(41例)。对照组采用甲状腺激素替代疗法,观察组采用促甲状腺激素抑制剂疗法。比较2组患者入组前、入组3个月、6个月后切除癌组织周围组织中TIPE2阳性细胞表达率、STAT3表达阳性率情况,比较2组患者入组前、入组后3个月、6个月血清游离甲状腺激素(FT4)、血清游离三碘甲状腺原氨酸(FT3)水平,比较2组患者入组后6个月、12个月、24个月、36个月肿瘤复发、转移率。结果 2组患者入组前年龄、性别、体重、体质量指数(BMI)、肿瘤病理类型、肿瘤分期、手术方式、血清FT3、FT4、切除肿瘤周围组织TIPE2、STAT3表达阳性率比较,差异无统计学意义(P>0.05)。2组患者入组治疗3个月后、6个月后,观察组切除癌组织周围组织中TIPE2阳性细胞表达率高于对照组(P<0.05),STAT3表达阳性率明显低于对照组(P<0.05);入组3个月、6个月对照组患者甲状腺激素T3、T4均低于观察组(P<0.05)。入组6个月、12个月2组患者肿瘤复发率或(和)转移率比较,差异无统计学意义(P>0.05);入组24个月、36个月后,观察组肿瘤复发率或(和)转移率低于对照组(P<0.05)。结论 TSH抑制疗法对甲状腺癌手术患者术后甲状腺功能的稳定作用明显优于甲状腺激素替代疗法,并能有效抑制切除癌组织周围组织中STAT3的阳性表达率,提高TIPE2阳性细胞表达率。TSH抑制疗法对维持患者术后治疗效果,提高患者预后具有较高的临床价值。Objective To investigate the effect of thyroid stimulating hormone inhibition therapy（TSHIT） on the progno- sis of thyroid cancer and the expression of TIPE2 and STAT3 in pericancerous tissues. Methods 86 patients with thyroid carci- noma were selected as the subjects. All patients underwent surgical resection and were divided into the control group（ n = 47） and the observation group（ n =41 ） according to whether they were treated with TSHIT. The control group was treated with thyroid hor- mone replacement therapy, while the observation group was treated with TSHIT. Before treatment,3 and 6 months after treatment, expression of TIPE2 and STAT3 in pericancerous tissues after resection of carcinoma were compared between the 2 groups. Before entering the group,3 and 6 months after entering the group, serum FT4 and FT3 level~ were compared between the 2 groups. 6 months, 12 months ,24 months,36 months after treatment, tumor recurrence and metastasis rates of the 2 groups were compared. Results The 2 groups in age,sex,body weight,body mass index（BMI） ,pathological type,tumor staging,surgical method,serum FT3, Fr4, TIPE2, STAT3 pericancerous tissues positive expression rates had no significant difference （P 〉 0.05 ）. After 3 months and 6 months of treatment,TIPE2 pericancerous tissues positive expression rate of the observation group was higher than the con- trol group（P 〈 0.05 ）, the positive expression rate of STAT3 was significantly lower than the control group （P 〈 0.05 ） ;After 3 months and 6 months of treatment, thyroid hormone T3 and T4 of the control group were lower than those of the observation group （ P 〈 0.05 ）. After 6 months and 12 months of treatment, tumor recurrence or（and） transfer rates of the 2 groups had no statisti- cally significant difference（P 〉 0.05 ） ;After 24 months and 36 months of treatment, recurrence rate or（and） the transfer rates of the observation group were lower than the control group（ P 〈 0.05 ）. Conclusion TSHIT can inhib

关 键 词：甲状腺癌 促甲状腺激素抑制疗法 甲状腺激素替代疗法 肿瘤坏死因子诱导蛋白8样蛋白2 信号转导子和转录激活因子 预后影响 

分 类 号：R736.1[医药卫生—肿瘤]